Stock Events

Stock Events

BioXcel Therapeutics 

$0.030000
155
+$0.00+2.74% 19:59 Today

Statistics

Day High
0.03
Day Low
0.021
52W High
2.48
52W Low
0.019
Volume
97,514
Avg. Volume
5,888,348
Mkt Cap
939,150
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 18Expected
Q2 2026
Next
-1.01
-0.82
-0.63
-0.44
Expected EPS
-1.01
Actual EPS
N/A

Financials

-10,887.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
642,000Revenue
-69.9MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BTAIQ. It's not an investment recommendation.
Apple
19
AAPL
Microsoft
19
MSFT
NVIDIA
18
NVDA
Palantir Technologies
18
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7B
Alkermes develops therapies for central nervous system (CNS) diseases, including schizophrenia and depression, overlapping with BioXcel's focus areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.44B
ACADIA Pharmaceuticals specializes in CNS disorders, particularly Parkinson’s disease psychosis, competing in the neuropsychiatric space.
Insmed
INSM
Mkt Cap24.27B
Insmed incorporates novel approaches to treat serious and rare diseases, including neurological disorders, potentially competing with BioXcel's innovative approaches.
BridgeBio Pharma
BBIO
Mkt Cap13.15B
BridgeBio Pharma targets genetic diseases and cancers with a precision medicine approach, indirectly competing in the innovation space for treatments.
Protagonist Therapeutics
PTGX
Mkt Cap9.06B
Protagonist Therapeutics is involved in developing peptide-based treatments that could compete with BioXcel's therapies in various indications.
Axsome Therapeutics
AXSM
Mkt Cap9.39B
Axsome Therapeutics focuses on developing treatments for central nervous system disorders, including depression and migraine, competing in BioXcel's market.
Voyager Therapeutics
VYGR
Mkt Cap150.96M
Voyager Therapeutics specializes in severe neurological diseases by developing gene therapies, offering a different approach but competing in the same therapeutic area.

About

BIOXCEL THERAPEUTICS INC
Show More
CEO
Vimal D. Mehta
Employees
29
Country
United States
ISIN
US09075P2048
WKN
000A40YSR

Listings

MU
DE
BX2.MU
MU
DE
BX20.MU
OTCM
US
BTAI
OTC Link
US
BTAIQ

0 Comments

Share your thoughts

FAQs

What is BioXcel Therapeutics stock price today?▼
The current price of BTAIQ is $0.03 USD — it has increased by +2.74% in the past 24 hours. Watch BioXcel Therapeutics stock price performance more closely on the chart.
What is BioXcel Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange BioXcel Therapeutics stocks are traded under the ticker BTAIQ.
What is BioXcel Therapeutics market cap?▼
Today BioXcel Therapeutics has the market capitalization of 939,150
When is the next BioXcel Therapeutics earnings date?▼
BioXcel Therapeutics is going to release the next earnings report on November 18, 2026.
What is BioXcel Therapeutics revenue for the last year?▼
BioXcel Therapeutics revenue for the last year amounts to 642,000 USD.
What is BioXcel Therapeutics net income for the last year?▼
BTAIQ net income for the last year is -69.9M USD.
How many employees does BioXcel Therapeutics have?▼
As of October 16, 2026, the company has 29 employees.
In which sector is BioXcel Therapeutics located?▼
BioXcel Therapeutics operates in the Health & Wellness sector.
When did BioXcel Therapeutics complete a stock split?▼
The last stock split for BioXcel Therapeutics was on February 10, 2025 with a ratio of 1:16.
Where is BioXcel Therapeutics headquartered?▼
BioXcel Therapeutics is headquartered in New Haven, United States.